| 个 人 简 历 |
◆ 基本情况
*
*
*
*
*
病理学与病理生理学
◆联系方式
*
◆ 教育背景
2016.9-
中美（河南）荷美尔肿瘤研究院
2012.9-
2008.9-2012.6：河南农业大学，药物制剂专业，获医学学士学位
◆ 参与课题
国家自然科学基金面上项目： 《Caspase-7通过新型靶基因抑制皮肤癌的调控机制研究》（项目编号：**，2017.07-2020.12，58万元）
国家自然科学基金面上项目： 《TAOK1激酶作为食管鳞癌潜在治疗靶点的功能研究》（项目编号：**，2020.01-2023.12，55万元）
◆ 所获奖励
奖学金：
◆ 国家专利
申请国家专利：《黄腐酚在制备蛋白激酶B抑制剂方面的应用》，第四发明人，专利号：ZL-2017-1-**.4。
◆ 国际会议
1. 韩国Korean Society for Molecular and Cellular Biology(KSMCB) 2019国际会议，时间：9.30-10.02，韩国首尔，论文海报展
2. 美国AACR 2019国际会议，时间：3.29-4.03，美国亚特兰大，论文海报展
◆ 发表文章
1.Song M#, Yoon G#, Choi JS, Kim E, Liu X, Oh HN,Chae JI, Lee MH, Shim JH. Janus kinase 2 inhibition by Licochalcone Bsuppresses esophageal squamous cell carcinoma growth. Phytother Res,2020 Mar 6. doi: 10.1002/ptr.6661.(3区 IF=4.087)
2.Song M#, Yin S#, Zhao R, Liu K, Kundu JK, Shim JH,Lee MH, Dong Z. (S)-10-Hydroxycamptothecin Inhibits Esophageal Squamous CellCarcinoma Growth In Vitro and In Vivo Via Decreasing Topoisomerase I EnzymeActivity. Cancers (Basel). 2019 Dec 6;11(12): 1964. (2区 IF=6.126)
3.Song M#, Bode AM#, Dong Z, Lee MH. AKT as aTherapeutic Target for Cancer. Cancer Research. 2019 Mar15;79(6):1019-1031. (1区，IF=8.378)
4.Song M#, Liu X#, Liu K#, Zhao R, HuangH, Shi Y, Zhang M, Zhou S, Xie H, Chen H, Li Y, Zheng Y, Wu Q, Liu F, Li E,Bode AM, Dong Z, Lee MH. Targeting AKT with oridonin inhibits growth ofesophageal squamous cell carcinoma in vitro and patient derived xenografts invivo. Mol Cancer Ther, 2018 Jul;17(7):1540-1553. (2区 IF=4.856)
5.Yin S#,Song M#, Zhao R, Liu X, Kang WK, Lee JM, Kim YE, Zhang C,Shim JH, Liu K, Dong Z, Lee MH. Xanthohumol Inhibits the Growth of Keratin 18 -Overexpressed Esophageal Squamous Cell Carcinoma in vitro and in vivo. FrontCell Dev Biol, 2020 May 19;8:366.(2区 IF=5.201)
6.Liu X#,Song M#, Wang P#, Zhao R, Chen H, Zhang M,Shi Y, Liu K, Liu F, Yang R, Li E, Bode AM, Dong Z, Lee MH. Targeted therapy ofthe AKT kinase inhibits esophageal squamous cell carcinoma growth in vitro andin vivo. International Journal of Cancer. 2019 Aug15;145(4):1007-1019. (2区 IF=4.982)
7.XinningZhang#, Mengqiu Song#, Joydeb Kumar Kundu,Mee-Hyun Lee, Zhen-Zhen Liu. PIM Kinase as an Executional Target in Cancer. JOURNALOF CANCER PREVENTION. 2018 Sep; 23(3):109-116.
8.Zhao R#,Huang H#, Choi BY#, Liu X, Zhang M, Zhou S, Song M,Yin F, Chen H, Shim JH, Bode AM, Dong Z, Lee MH. Cell growth inhibition by3-deoxysappanchalcone is mediated by directly targeting the TOPK signalingpathway in colon cancer. Phytomedicine. 2019 Aug;61:152813.
9.Shi Y#,Liu X#, Fredimoses M#, Song M, Chen H, LiuK, Lee MH, Dong Z. FGFR2 regulation by picrasidine Q inhibits the cell growthand induces apoptosis in esophageal squamous cell carcinoma. J Cell Biochem,2018 Feb;119(2):2231-2239.
10. Li H, Lee MH, Liu K, Wang T, Song M, HanY, Yao K, Xie H, Zhu F, Grossmann M, Cleary MP, Chen W, Bode AM, Dong Z.Inhibiting breast cancer by targeting the thromboxane A2 pathway. NPJ PrecisOncol. 2017 Apr 3;1(1):8.
11. Shin SH, Lim DY, Reddy K, Malakhova M, Liu F, Wang T, SongM, Chen H, Bae KB, Ryu J, Liu K, Lee MH, Bode AM, Dong Z.A. SmallMolecule Inhibitor of the β-Catenin-TCF4 Interaction Suppresses ColorectalCancer Growth In Vitro and In Vivo. EBioMedicine. 2017 Nov;25:22-31.
